Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer

Authors:

Abstract
Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer Andrés Redondo,1,* Virginia Martínez,1,* Pilar Zamora,1 Beatriz Castelo,1 Alvaro Pinto,1 Patricia Cruz,1 Oliver Higuera,1 Marta Mendiola,2 David Hardisson,3 Enrique Espinosa11Medical Oncology Department, 2Translational Oncology and Molecular Pathology Laboratory, 3Pathology Department, University Hospital La Paz (IdiPAZ), Madrid, Spain *These authors contributed equally to this workBackground: Bevacizumab plus taxane chemotherapy improves progression-free survival (PFS) versus taxane monotherapy in the first-line treatment of HER2-negative metastatic breast cancer (MBC) and appears promising in the second-line setting. This retrospective analysis evaluated the efficacy and safety of this combination in a real-world setting.Patients and methods: Eligible patients received bevacizumab (10 mg/kg days 1 and 15, every 28 days) plus paclitaxel (80 mg/m2 days 1, 8, and 15, every 28 days) as first-line therapy for MBC, or as subsequent lines, including bevacizumab continuation therapy, at La Paz University Hospital between August 2007 and October 2012. End points included objective response rate (ORR), PFS, overall survival (OS), and safety.Results: Seventy-eight patients were included. Median PFS was 12.8 months for patients receiving first-line treatment and 9.3 months for subsequent lines. Forty-five patients (57.7%) continued bevacizumab after stopping paclitaxel, and had significantly longer PFS and OS than those who did not (hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.248–0.653, P

This publication has 12 references indexed in Scilit: